4D Pharma PLC
LSE:DDDD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
BAIC Motor Corp Ltd
OTC:BCCMY
|
CN |
|
Tianneng Power International Ltd
HKEX:819
|
CN |
|
V
|
VEON Ltd
LSE:0RO7
|
NL |
|
C
|
CDG Petchem Ltd
BSE:534796
|
IN |
4D Pharma PLC
Research & Development
4D Pharma PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
4D Pharma PLC
LSE:DDDD
|
Research & Development
-£14.6m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Research & Development
-£6.6B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-8%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Research & Development
-$13.8B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-9%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Research & Development
-$151m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-15%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Research & Development
-£15.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-17%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
4D Pharma PLC
Glance View
4D Pharma Plc is a pharmaceutical company, which engages in the development of live bio therapeutics. The firm's LBPs are biologics based on live organisms, namely single strains of bacteria. The company has developed its research to build MicroRx, which is a discovery platform that is able to select those bacteria that have a therapeutic effect in specific diseases. The company uses MicroRx to interrogate its library of bacterial isolates to identify LBPs. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) disease. The company is conducting a phase I/II clinical study of MRx-4DP0004 in patients with poorly controlled asthma.
See Also
What is 4D Pharma PLC's Research & Development?
Research & Development
-14.6m
GBP
Based on the financial report for Dec 31, 2021, 4D Pharma PLC's Research & Development amounts to -14.6m GBP.
What is 4D Pharma PLC's Research & Development growth rate?
Research & Development CAGR 5Y
-20%
Over the last year, the Research & Development growth was 11%. The average annual Research & Development growth rates for 4D Pharma PLC have been 9% over the past three years , -20% over the past five years .
